- Email: [email protected]
Corrigendum to “Abstracts Presented at EACPT 2017”
Clinical Therapeutics/Volume ], Number ], 2017
Corrigendum Corrigendum to “Abstracts Presented at EACPT 2017” Clin Ther 2017;39:e66 J. Gafsi2; F. Gueyffier2,3; and I. Marchant1 1
Valparaiso University, Valparaiso, Chile; 2Claude Bernard University, Lyon, France; and 3Lyon University Hospitals, Lyon, France
The authors regret that there was an error in the supplied table, though the conclusion was not impacted. The corrected table is printed here. Table 1.
Table 1. Economic assessment of ESC/EAS Guidelines and ACC/AHA Guidelines. N ¼ 20536 Number of MVE expected without treatment: 7108 Target strategy Fixed-dose strategy Ratio Target/Fixed dose strategies
Benefits
Costs (M€)
Patients MVE MVE Relative treated estimated avoided Risk Treatment Monitoring MVE Total 16638 13384 1,2
5603 5145 1,1
1505 1963 0,8
0,79 0,72
27 31 0,8
7 5 1,4
19 18 1,1
52 54 1,0
The authors would like to apologise for any inconvenience caused.
http://dx.doi.org/10.1016/j.clinthera.2017.07.014
] 2017
1
Corrigendum Corrigendum to “Abstracts Presented at EACPT 2017” Clin Ther 2017;39:e66 J. Gafsi2; F. Gueyffier2,3; and I. Marchant1 1
Valparaiso University, Valparaiso, Chile; 2Claude Bernard University, Lyon, France; and 3Lyon University Hospitals, Lyon, France
The authors regret that there was an error in the supplied table, though the conclusion was not impacted. The corrected table is printed here. Table 1.
Table 1. Economic assessment of ESC/EAS Guidelines and ACC/AHA Guidelines. N ¼ 20536 Number of MVE expected without treatment: 7108 Target strategy Fixed-dose strategy Ratio Target/Fixed dose strategies
Benefits
Costs (M€)
Patients MVE MVE Relative treated estimated avoided Risk Treatment Monitoring MVE Total 16638 13384 1,2
5603 5145 1,1
1505 1963 0,8
0,79 0,72
27 31 0,8
7 5 1,4
19 18 1,1
52 54 1,0
The authors would like to apologise for any inconvenience caused.
http://dx.doi.org/10.1016/j.clinthera.2017.07.014
] 2017
1